#obesity drug
Related Stories (3)
Hims' obesity drug business may get boost as employers drop coverage - Reuters
Hims' obesity drug business may get boost as employers drop coverage Reuters
June 25, 2026Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
February 23, 2026Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
February 23, 2026Related Pages (4)
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
Novo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects future sales and market position. Eli Lilly's shares saw a rise. I
Novo Nordisk Stock Hits 52-Week Low After Weight-Loss Drug Falls Short Against Eli Lilly's
BenzingaEspañaItalia대한민국日本FrançaisMy AccountBenzinga EdgeBenzinga ResearchBenzinga ProLoginGet Benzinga Pro Data & APIsEventsPremarketAdvertiseContributeEspañaItalia대한민국日本FrançaisLoginRegisterBenzinga
Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly
Take advantage of our newsletter subscription and stay informed on the go!
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa